Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 9Breast 7Lymphoid 6Sarcoma 4Genitourinary 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 17Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Paclitaxel 7Biopsy 7Nivolumab 6atezolizumab 5Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Practice Guidelines as Topic 4Pemetrexed 4Oxaliplatin 4Cyclophosphamide 4Carboplatin 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3Radiotherapy 3Radiation 3Leucovorin 3Irinotecan 3Ipilimumab 3Interviews as Topic 3Fluorouracil 3trastuzumab deruxtecan 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × liposomal doxorubicin × Tumor-Agnostic × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡